嗜酸粒细胞性食管炎中的生物制剂。
Biologics in eosinophilic esophagitis.
机构信息
University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy.
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Division of Allergy and Immunology, Cincinnati, OH, USA.
出版信息
Curr Opin Allergy Clin Immunol. 2021 Jun 1;21(3):292-296. doi: 10.1097/ACI.0000000000000741.
PURPOSE OF REVIEW
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the oesophagus whose incidence is on the rise. Despite maximal use of guideline-based therapies including food elimination diets and steroids, many patients remain symptomatic. This review serves to summarize safety and efficacy of monoclonal antibodies in treatment of EoE.
RECENT FINDINGS
There has been an increasing number of biologics under consideration for EoE and several that have undergone clinical trials. mAbs that target specific effectors involved in the disease may offer additional clinical and histologic benefit. In addition, they offer a more benign adverse effect profile than traditional therapies.
SUMMARY
Biologics for treatment of EoE may result in symptom and histologic improvement and has the potential to treat disease with minimal side effects.
目的综述
嗜酸性食管炎（EoE）是一种食管的慢性炎症性疾病，其发病率正在上升。尽管最大程度地使用了基于指南的治疗方法，包括食物消除饮食和类固醇，但许多患者仍有症状。本文综述总结了单克隆抗体治疗 EoE 的安全性和疗效。
最近的发现
有越来越多的生物制剂被考虑用于 EoE，并且有一些已经进行了临床试验。针对参与疾病的特定效应物的 mAbs 可能提供额外的临床和组织学益处。此外，它们比传统疗法具有更良性的不良反应谱。
总结
用于治疗 EoE 的生物制剂可能会导致症状和组织学改善，并有可能以最小的副作用治疗疾病。
Zotero 插件